Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.41 |
| ▸ | ACLY | P53396 | 6/20 | 0.40 |
| ▸ | F2 | P00734 | 3/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1056064 | 0.87 | HSD17B10 (0.48) | CA1CA2MEP1BACLYF2 | |
| SCHEMBL23747994 | 0.81 | CA1 (0.35) | CA1CA2CA9TDP1CA12 | |
| SCHEMBL184213 | 0.81 | CA1 (0.68) | CA1CA2ACLYF2PRSS1 | |
| SCHEMBL10988183 | 0.79 | CA1 (0.66) | CA1CA2ACLYF2PRSS1 | |
| SCHEMBL2268180 | 0.78 | CA1 (0.55) | CA1CA2CA9TDP1CA12 | |
| SCHEMBL29619934 | 0.78 | CA1 (0.55) | CA1CA2CA9TDP1CA12 | |
| SCHEMBL1019730 | 0.78 | CA1 (0.54) | CA1CA2ACLYF2PRSS1 | |
| SCHEMBL21954756 | 0.78 | ACLY (0.49) | CA1CA2ACLY | |
| SCHEMBL21999634 | 0.78 | ACLY (0.49) | CA1CA2ACLYF2PRSS1 | |
| SCHEMBL23413882 | 0.78 | CA1 (0.43) | CA1CA2MEP1BACLYCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445440-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| EP-2539333-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104266-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | CA1 2063/4885CA2 2818/4885MEP1B 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.